EHC

Encompass Health Corp (EHC) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Encompass Health Corporation is the nation's largest owner and operator of inpatient rehabilitation hospitals (IRFs), operating 168 facilities across 38 states and Puerto Rico. The company operates as a single reportable segment focused on inpatient rehabilitation services, with significant concentrations in Florida and Texas.

Key Financial Metrics

Margins: Operating expenses as a percentage of net operating revenues decreased to 82.2% in Q2 2025 from 83.4% in Q2 2024. Salaries and benefits represented 52.7% of revenues in Q2 2025.

Material Changes vs. Prior Period

• Revenue Growth: Net operating revenues increased 12.0% in Q2 2025 and 11.3% YTD, driven by a 7.2% increase in discharges (Q2) and a 4.2% increase in net patient revenue per discharge.
• Profitability: Net income attributable to Encompass Health rose 24.5% in Q2 and 29.6% YTD. Pre-tax income from continuing operations increased 27.3% in Q2.
• Volume Drivers: Growth was supported by same-store discharge increases (4.7% in Q2) and new facility openings in Athens, GA, and Fort Myers, FL, as well as capacity expansions adding 51 beds.
• Expense Management: Salaries and benefits increased 9.6% in Q2 but decreased as a percentage of revenue due to improved efficiency (lower employees per occupied bed) and reduced reliance on contract labor.
• Noncontrolling Interests: Net income attributable to noncontrolling interests increased significantly (32.1% in Q2) due to higher profitability in joint venture hospitals.

Guidance, Outlook, and Risks

• Capital Expenditures: The company expects to spend approximately $785 million to $820 million on capital expenditures in 2025, with roughly $215-$225 million classified as nondiscretionary maintenance.
• Dividends and Buybacks: The board increased the quarterly dividend to $0.19 per share (payable Oct 2025). Approximately $433 million remains available under the $500 million stock repurchase authorization.
• Regulatory Outlook (CMS): The 2026 Final IRF Rule is expected to result in a net 2.9% increase to Medicare payment rates effective October 1, 2025. However, the company faces uncertainty regarding the CMS Review Choice Demonstration (RCD) program in Alabama, where claim validation rates have not met opt-out thresholds in recent cycles.
• Tax Legislation: The "One Big Beautiful Bill Act" (OBBBA) signed in July 2025 is expected to generate approximately $50 million in cash tax savings for 2025 due to extended bonus depreciation and R&D expensing provisions.
• Risks: Key risks include Medicare reimbursement changes, staffing shortages, regulatory audits (including potential qui tam lawsuits), and the expansion of the RCD program to other states.

Investor Verification Checklist

• Medicare Reimbursement Impact: Verify the actual financial impact of the 2026 IRF Rule and the ongoing RCD audit results in Alabama on future cash flows.
• Joint Venture Performance: Review the specific profitability drivers of joint ventures, given the significant increase in noncontrolling interest income.
• Capital Allocation: Monitor the execution of the $785M+ capital expenditure plan and the pace of stock repurchases against the remaining $433M authorization.
• Staffing Costs: Track the trend of contract labor usage and sign-on bonuses to ensure salary expense ratios remain stable despite volume growth.
• Debt Covenants: Confirm continued compliance with the 4.50x leverage ratio and 3.0x interest coverage ratio under the credit agreement.